Tags: Biogen | FDA | probe | Alzheimers | Aduhelm | approbal

FDA Chief Seeks Federal Probe Into Approval of Alzheimer's Drug

A magnifying glass looking at FDA
(Dreamstime)

Friday, 09 July 2021 01:53 PM EDT

A top official at the U.S. drug regulator on Friday called for a federal probe into the interactions between the agency's representatives and Biogen Inc that led to the approval of the company's Alzheimer's disease drug last month.

Janet Woodcock, acting commissioner of the Food and Drug Administration (FDA), in a letter posted on Twitter, asked the Office of the Inspector General at the Department of Health and Human Services to probe if any interactions between FDA staff and Biogen were inconsistent with the agency's policies.

The FDA has drawn sharp criticism for its broad approval of the drug last month without proof of clear benefit against the disease.

Stat News first reported that Woodcock had called for a probe.

© 2025 Thomson/Reuters. All rights reserved.


Health-News
A top official at the U.S. drug regulator on Friday called for a federal probe into the interactions between the agency's representatives and Biogen Inc that led to the approval of the company's Alzheimer's disease drug last month. Janet Woodcock, acting commissioner of the...
Biogen, FDA, probe, Alzheimers, Aduhelm, approbal
120
2021-53-09
Friday, 09 July 2021 01:53 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved